Innate immune recognition against SARS-CoV-2.
Innate immune recognition against SARS-CoV-2.
复制标题
DOI：
10.1186/s41232-023-00259-5
复制
发表时间：
2023-01-26
影响因子：
8.1
通讯作者：
中科院分区：
文献类型：
--
作者：
严重急性呼吸道综合征冠状病毒-2（SARS-CoV-2）是称为2019年冠状病毒病（COVID-19）的大流行性急性呼吸道疾病的致病病毒。大多数感染者无症状或症状轻微，但有些患者表现出严重和严重的全身炎症，包括组织损伤和多器官功能衰竭。对病原体的免疫反应决定了临床进程。通常，先天免疫应答的激活由识别病原体相关分子模式（PAMP）以及宿主损伤相关分子模式（DAMP）的宿主模式识别受体（PRR）介导，这导致I型和III型干扰素（IFN）和促炎细胞因子的下游基因诱导程序的激活以诱导抗病毒活性。然而，这些反应的过度激活可能导致有害的炎症。在这里，我们回顾了我们对SARS-CoV-2感染的先天免疫反应的最新进展，特别是在先天识别和随后的COVID-19免疫病理学炎症方面。
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is the causative virus of pandemic acute respiratory disease called coronavirus disease 2019 (COVID-19). Most of the infected individuals have asymptomatic or mild symptoms, but some patients show severe and critical systemic inflammation including tissue damage and multi-organ failures. Immune responses to the pathogen determine clinical course. In general, the activation of innate immune responses is mediated by host pattern-recognition receptors (PRRs) that recognize pathogen-associated molecular patterns (PAMPs) as well as host damage-associated molecular patterns (DAMPs), which results in the activation of the downstream gene induction programs of types I and III interferons (IFNs) and proinflammatory cytokines for inducing antiviral activity. However, the excessive activation of these responses may lead to deleterious inflammation. Here, we review the recent advances in our understanding of innate immune responses to SARS-CoV-2 infection, particularly in terms of innate recognition and the subsequent inflammation underlying COVID-19 immunopathology.
登录
查看更多内容
危及生命的Covid-19患者中针对I型IFN的自身抗体。
DOI：
10.1126/science.abd4585
发表时间：
2020-10-23
期刊：
Science (New York, N.Y.)
影响因子：
--
作者：
Bastard P;Rosen LB;Zhang Q;Michailidis E;Hoffmann HH;Zhang Y;Dorgham K;Philippot Q;Rosain J;Béziat V;Manry J;Shaw E;Haljasmägi L;Peterson P;Lorenzo L;Bizien L;Trouillet-Assant S;Dobbs K;de Jesus AA;Belot A;Kallaste A;Catherinot E;Tandjaoui-Lambiotte Y;Le Pen J;Kerner G;Bigio B;Seeleuthner Y;Yang R;Bolze A;Spaan AN;Delmonte OM;Abers MS;Aiuti A;Casari G;Lampasona V;Piemonti L;Ciceri F;Bilguvar K;Lifton RP;Vasse M;Smadja DM;Migaud M;Hadjadj J;Terrier B;Duffy D;Quintana-Murci L;van de Beek D;Roussel L;Vinh DC;Tangye SG;Haerynck F;Dalmau D;Martinez-Picado J;Brodin P;Nussenzweig MC;Boisson-Dupuis S;Rodríguez-Gallego C;Vogt G;Mogensen TH;Oler AJ;Gu J;Burbelo PD;Cohen JI;Biondi A;Bettini LR;D'Angio M;Bonfanti P;Rossignol P;Mayaux J;Rieux-Laucat F;Husebye ES;Fusco F;Ursini MV;Imberti L;Sottini A;Paghera S;Quiros-Roldan E;Rossi C;Castagnoli R;Montagna D;Licari A;Marseglia GL;Duval X;Ghosn J;HGID Lab;NIAID-USUHS Immune Response to COVID Group;COVID Clinicians;COVID-STORM Clinicians;Imagine COVID Group;French COVID Cohort Study Group;Milieu Intérieur Consortium;CoV-Contact Cohort;Amsterdam UMC Covid-19 Biobank;COVID Human Genetic Effort;Tsang JS;Goldbach-Mansky R;Kisand K;Lionakis MS;Puel A;Zhang SY;Holland SM;Gorochov G;Jouanguy E;Rice CM;Cobat A;Notarangelo LD;Abel L;Su HC;Casanova JL
通讯作者：
Casanova JL
影响因子：
29.7
作者：
Brubaker SW;Bonham KS;Zanoni I;Kagan JC
通讯作者：
Kagan JC
影响因子：
30.5
作者：
Buerckstuemmer, Tilmann;Baumann, Christoph;Superti-Furga, Giulio
通讯作者：
Superti-Furga, Giulio
影响因子：
6.7
作者：
Chao, Chiao-Hsuan;Wu, Wei-Chueh;Yeh, Trai-Ming
通讯作者：
Yeh, Trai-Ming
影响因子：
24.8
作者：
Bastard P;Gervais A;Le Voyer T;Rosain J;Philippot Q;Manry J;Michailidis E;Hoffmann HH;Eto S;Garcia-Prat M;Bizien L;Parra-Martínez A;Yang R;Haljasmägi L;Migaud M;Särekannu K;Maslovskaja J;de Prost N;Tandjaoui-Lambiotte Y;Luyt CE;Amador-Borrero B;Gaudet A;Poissy J;Morel P;Richard P;Cognasse F;Troya J;Trouillet-Assant S;Belot A;Saker K;Garçon P;Rivière JG;Lagier JC;Gentile S;Rosen LB;Shaw E;Morio T;Tanaka J;Dalmau D;Tharaux PL;Sene D;Stepanian A;Megarbane B;Triantafyllia V;Fekkar A;Heath JR;Franco JL;Anaya JM;Solé-Violán J;Imberti L;Biondi A;Bonfanti P;Castagnoli R;Delmonte OM;Zhang Y;Snow AL;Holland SM;Biggs C;Moncada-Vélez M;Arias AA;Lorenzo L;Boucherit S;Coulibaly B;Anglicheau D;Planas AM;Haerynck F;Duvlis S;Nussbaum RL;Ozcelik T;Keles S;Bousfiha AA;El Bakkouri J;Ramirez-Santana C;Paul S;Pan-Hammarström Q;Hammarström L;Dupont A;Kurolap A;Metz CN;Aiuti A;Casari G;Lampasona V;Ciceri F;Barreiros LA;Dominguez-Garrido E;Vidigal M;Zatz M;van de Beek D;Sahanic S;Tancevski I;Stepanovskyy Y;Boyarchuk O;Nukui Y;Tsumura M;Vidaur L;Tangye SG;Burrel S;Duffy D;Quintana-Murci L;Klocperk A;Kann NY;Shcherbina A;Lau YL;Leung D;Coulongeat M;Marlet J;Koning R;Reyes LF;Chauvineau-Grenier A;Venet F;Monneret G;Nussenzweig MC;Arrestier R;Boudhabhay I;Baris-Feldman H;Hagin D;Wauters J;Meyts I;Dyer AH;Kennelly SP;Bourke NM;Halwani R;Sharif-Askari NS;Dorgham K;Sallette J;Sedkaoui SM;AlKhater S;Rigo-Bonnin R;Morandeira F;Roussel L;Vinh DC;Ostrowski SR;Condino-Neto A;Prando C;Bonradenko A;Spaan AN;Gilardin L;Fellay J;Lyonnet S;Bilguvar K;Lifton RP;Mane S;HGID Lab;COVID Clinicians;COVID-STORM Clinicians;NIAID Immune Response to COVID Group;NH-COVAIR Study Group;Danish CHGE;Danish Blood Donor Study;St. James's Hospital;SARS CoV2 Interest group;French COVID Cohort Study Group;Imagine COVID-Group;Milieu Intérieur Consortium;CoV-Contact Cohort;Amsterdam UMC Covid-19;Biobank Investigators;COVID Human Genetic Effort;CONSTANCES cohort;3C-Dijon Study;Cerba Health-Care;Etablissement du Sang study group;Anderson MS;Boisson B;Béziat V;Zhang SY;Vandreakos E;Hermine O;Pujol A;Peterson P;Mogensen TH;Rowen L;Mond J;Debette S;de Lamballerie X;Duval X;Mentré F;Zins M;Soler-Palacin P;Colobran R;Gorochov G;Solanich X;Susen S;Martinez-Picado J;Raoult D;Vasse M;Gregersen PK;Piemonti L;Rodríguez-Gallego C;Notarangelo LD;Su HC;Kisand K;Okada S;Puel A;Jouanguy E;Rice CM;Tiberghien P;Zhang Q;Cobat A;Abel L;Casanova JL
通讯作者：
Casanova JL